Novo Nordisk A/SNYSE:NVO
- LAST PRICE109.1400
- TODAY'S CHANGE (%)-0.5800 (-0.5286%)
- Bid / Lots109.1300/ 6
- Ask / Lots109.1700/ 6
- Open / Previous Close107.9750 / 109.7200
- Day Range
- 52 Week Range
- Volume2,749,715
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NVO |
|---|---|---|
| 09:32 ET | 10581 | 107.91 |
| 09:33 ET | 142592 | 108.09 |
| 09:35 ET | 38024 | 107.795 |
| 09:37 ET | 35835 | 108.245 |
| 09:39 ET | 39702 | 108.46 |
| 09:42 ET | 22283 | 108.565 |
| 09:44 ET | 12957 | 108.39 |
| 09:46 ET | 36462 | 108.3 |
| 09:48 ET | 40162 | 108.39 |
| 09:50 ET | 15288 | 108.37 |
| 09:51 ET | 24074 | 108.31 |
| 09:53 ET | 24141 | 108.44 |
| 09:55 ET | 27848 | 108.37 |
| 09:57 ET | 31670 | 108.58 |
| 10:00 ET | 21697 | 108.53 |
| 10:02 ET | 40645 | 108.51 |
| 10:04 ET | 36387 | 108.43 |
| 10:06 ET | 19657 | 108.4 |
| 10:08 ET | 45048 | 108.44 |
| 10:09 ET | 24710 | 108.36 |
| 10:11 ET | 37749 | 108.4 |
| 10:13 ET | 29415 | 108.36 |
| 10:15 ET | 21995 | 108.4519 |
| 10:18 ET | 28529 | 108.3401 |
| 10:20 ET | 26222 | 108.3637 |
| 10:22 ET | 17185 | 108.4 |
| 10:24 ET | 17663 | 108.39 |
| 10:26 ET | 20847 | 108.45 |
| 10:27 ET | 21293 | 108.55 |
| 10:29 ET | 25843 | 108.5002 |
| 10:31 ET | 30795 | 108.335 |
| 10:33 ET | 54241 | 108.445 |
| 10:36 ET | 17897 | 108.45 |
| 10:38 ET | 15300 | 108.54 |
| 10:40 ET | 18476 | 108.49 |
| 10:42 ET | 18379 | 108.55 |
| 10:44 ET | 14934 | 108.49 |
| 10:45 ET | 60223 | 108.4175 |
| 10:47 ET | 52622 | 108.59 |
| 10:49 ET | 25301 | 108.58 |
| 10:51 ET | 14099 | 108.645 |
| 10:54 ET | 28566 | 108.73 |
| 10:56 ET | 18447 | 108.83 |
| 10:58 ET | 159799 | 108.96 |
| 11:00 ET | 33302 | 109.065 |
| 11:02 ET | 47825 | 108.995 |
| 11:03 ET | 36617 | 109.17 |
| 11:05 ET | 56540 | 109.39 |
| 11:07 ET | 12524 | 109.42 |
| 11:09 ET | 116305 | 109.43 |
| 11:12 ET | 30738 | 109.18 |
| 11:14 ET | 30169 | 109.17 |
| 11:16 ET | 15528 | 109.04 |
| 11:18 ET | 8259 | 108.945 |
| 11:20 ET | 13250 | 109 |
| 11:21 ET | 27341 | 109.075 |
| 11:23 ET | 20309 | 109.055 |
| 11:25 ET | 37300 | 109.125 |
| 11:27 ET | 11332 | 109.2 |
| 11:30 ET | 14020 | 109.09 |
| 11:32 ET | 24732 | 109.135 |
| 11:34 ET | 12481 | 109.16 |
| 11:36 ET | 15618 | 109.14 |
| 11:38 ET | 6420 | 109.14 |
Yesterday
DJ Novo Nordisk A/S Stock Falls Monday, Underperforms Market, from 23 hours ago by Dow Jones
23 hours ago by Dow JonesDJ This Pharma Stock Is Rising. The Weight-Loss Drugs Race Has Widened Beyond Lilly, Novo. -- Barrons.com, from 9:59AM ET on Monday Nov 04, 2024 by Dow Jones
9:59AM ET on Monday Nov 04, 2024 by Dow JonesDJ Novo Nordisk's Drug Prices and Production Capacity in Focus -- Earnings Preview, from 8:51AM ET on Monday Nov 04, 2024 by Dow Jones
8:51AM ET on Monday Nov 04, 2024 by Dow JonesDJ Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ, from 7:00AM ET on Monday Nov 04, 2024 by Dow Jones
7:00AM ET on Monday Nov 04, 2024 by Dow JonesDJ This Pharma Stock Is Soaring 21%. The Weight-Loss Drugs Race Has Widened Beyond Lilly, Novo. -- Barrons.com, from 6:27AM ET on Monday Nov 04, 2024 by Dow Jones
6:27AM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Novo Nordisk A/S | 370.7B | 37.2x | +18.50% |
Alnylam Pharmaceuticals Inc | 34.8B | -102.0x | --- |
Catalent Inc | 10.7B | -10.2x | --- |
Royalty Pharma PLC | 16.1B | 18.1x | +1.83% |
Perrigo Company PLC | 3.5B | -30.3x | --- |
Jazz Pharmaceuticals PLC | 6.8B | 18.9x | -3.53% |
Company Information
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Contact Information
- Headquarters
- Novo Alle 1BAGSVAERD, Denmark 2880
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Helge Lund
- President, Chief Executive Officer
- Lars Fruergaard Joergensen
- Vice Chairman of the Board
- Henrik Poulsen
- Chief Financial Officer, Executive Vice President
- Karsten Munk Knudsen
- Executive Vice President - International Operations
- Maziar Doustdar
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $370.7B |
|---|---|
Revenue (TTM) | $37.6B |
Shares Outstanding | 3.4B |
Dividend Yield | 1.33% |
Annual Dividend Rate | 1.4462 USD |
Ex-Dividend Date | 08-16-24 |
Pay Date | 08-26-24 |
Beta | 0.43 |
EPS | $2.93 |
Book Value | $3.49 |
P/E Ratio | 37.2x |
Price/Sales (TTM) | 9.8 |
Price/Cash Flow (TTM) | 25.6x |
Operating Margin | 43.20% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
